Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 14/20 | 0.75 |
| ▸ | SIK2 | Q9H0K1 | 12/20 | 0.75 |
| ▸ | SIK3 | Q9Y2K2 | 12/20 | 0.75 |
| ▸ | SIK1 | P57059 | 10/20 | 0.75 |
| ▸ | SRC | P12931 | 6/20 | 0.72 |
| ▸ | PKMYT1 | Q99640 | 3/20 | 0.70 |
| ▸ | KIT | P10721 | 4/20 | 0.68 |
| ▸ | BCR | P11274 | 3/20 | 0.68 |
| ▸ | EPHB6 | O15197 | 2/20 | 0.68 |
| ▸ | EGFR | P00533 | 2/20 | 0.68 |
| ▸ | LCK | P06239 | 2/20 | 0.68 |
| ▸ | FYN | P06241 | 2/20 | 0.68 |
| ▸ | CSF1R | P07333 | 2/20 | 0.68 |
| ▸ | YES1 | P07947 | 2/20 | 0.68 |
| ▸ | LYN | P07948 | 2/20 | 0.68 |
| ▸ | RET | P07949 | 2/20 | 0.68 |
| ▸ | HCK | P08631 | 2/20 | 0.68 |
| ▸ | BRAF | P15056 | 2/20 | 0.68 |
| ▸ | EPHA1 | P21709 | 2/20 | 0.68 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30144989 | 1.00 | ABL1 (0.75) | ABL1SIK2SIK3SIK1SRC | |
| SCHEMBL14141736 | 0.93 | ABL1 (0.73) | ABL1SIK2SIK3SIK1SRC | |
| SCHEMBL14665835 | 0.92 | ABL1 (0.64) | ABL1SIK2SIK3SIK1SRC | |
| SCHEMBL29885048 | 0.91 | ABL1 (0.73) | ABL1SIK2SIK3SIK1SRC | |
| SCHEMBL3396435 | 0.91 | ABL1 (0.73) | ABL1SIK2SIK3SIK1SRC | |
| SCHEMBL12438117 | 0.91 | ABL1 (0.73) | ABL1SIK2SIK3SIK1SRC | |
| SCHEMBL18971581 | 0.90 | ABL1 (0.72) | ABL1SIK2SIK3SIK1SRC | |
| Water SCHEMBL3226546 | 0.90 | ABL1 (0.72) | ABL1SIK2SIK3SIK1SRC | |
| SCHEMBL4252892 | 0.90 | ABL1 (0.69) | ABL1SIK2SIK3SIK1SRC | |
| SCHEMBL4257532 | 0.89 | SIK2 (0.67) | ABL1SIK2SIK3SIK1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2532662-B1 | SYNTHESIS PROCESS OF DASATINIB AND INTERMEDIATE THEREOF | NANJING CAVENDISH BIO ENGINEERING TECHNOLOGY CO LTD (CN) | 2016-01-27 | — | — | EP | claimed |
| US-9108954-B2 | Synthesis process of dasatinib and intermediate thereof | NAN JING CAVENDISH BIO-ENGINEERING TECHNOLOGY CO., LTD. (CN) | 2015-08-18 | — | — | US | claimed |
| US-20130030177-A1 | SYNTHESIS PROCESS OF DASATINIB AND INTERMEDIATE THEREOF | Nan Jing Cavendish Bio-Engineering Technology Co. Ltd. (CN) | 2013-01-31 | — | — | US | claimed |
| EP-2532662-A1 | SYNTHESIS PROCESS OF DASATINIB AND INTERMEDIATE THEREOF | Nanjing Cavendish Bio-Engineering Technology Co., Ltd. (CN) | 2012-12-12 | — | — | EP | claimed |
| CN-101812060-B | Simple novel method for preparing high-purity Sprycel, and intermediate compound | NANJING CAVENDISH BIOENGINEERING TECHNOLOGY CO LTD | 2011-08-17 | — | — | CN | claimed |
| CN-101812060-A | Simple novel method for preparing high-purity Sprycel, and intermediate compound | NANJING CAVENDISH BIO ENGINEERING TECHNOLOGY CO LTD | 2010-08-25 | — | — | CN | claimed |
| US-20090105250-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-04-23 | — | — | US | claimed |
| EP-1841431-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM, LLC (BM) | 2007-10-10 | — | — | EP | claimed |
| WO-2006081172-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2006-08-03 | — | — | WO | claimed |
| EP-3715346-B1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | DANA FARBER CANCER INST INC (US) | 2024-01-03 | — | — | EP | disclosed |
| CN-113727981-B | Kinase inhibitor, preparation, pharmaceutical composition and application thereof | 湖南华纳大药厂股份有限公司 | 2023-01-20 | — | — | CN | disclosed |
| CN-113727981-A | Kinase inhibitor, preparation, pharmaceutical composition and application thereof | 湖南华纳大药厂股份有限公司 | 2021-11-30 | — | — | CN | disclosed |
| CN-112409349-A | Kinase inhibitor, preparation, pharmaceutical composition and application thereof | 湖南华纳大药厂股份有限公司 | 2021-02-26 | — | — | CN | disclosed |
| EP-2532662-B1 | SYNTHESIS PROCESS OF DASATINIB AND INTERMEDIATE THEREOF | NANJING CAVENDISH BIO ENGINEERING TECHNOLOGY CO LTD (CN) | 2016-01-27 | — | — | EP | disclosed |
| WO-2009076373-A1 | HETEROCYCLIC KINASE INHIBITORS | CONCERT PHARMACEUTICALS INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| US-20090149399-A1 | HETEROCYCLIC KINASE INHIBITORS | CONCERT PHARMACEUTICALS INC. (US) | 2009-06-11 | — | — | US | disclosed |
| US-20090149399-A1 | HETEROCYCLIC KINASE INHIBITORS | CONCERT PHARMACEUTICALS INC. (US) | 2009-06-11 | — | — | US | disclosed |
| US-20090105250-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-04-23 | — | — | US | disclosed |
| EP-1841431-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM, LLC (BM) | 2007-10-10 | — | — | EP | disclosed |
| WO-2006081172-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2006-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105250-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | ABL1, BCR, PDGFRB | ABL1 1/4885SIK2 832/4885SIK3 1485/4885 |
| US-20090149399-A1 | HETEROCYCLIC KINASE INHIBITORS | ABL1, ABL2, SRC | ABL1 1/4885SIK2 265/4885SIK3 521/4885 |
| US-20130030177-A1 | SYNTHESIS PROCESS OF DASATINIB AND INTERMEDIATE THEREOF | ABL1, YES1, ABL2 | ABL1 1/4885SIK2 135/4885SIK3 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.